Delivery Systems, Diabetes, Diabetes Mellitus, Type 2
Conditions
Brief summary
This study is conducted in Asia. The aim of this observational study is to evaluate safety, efficacy and convenience in using NovoMix® 30 FlexPen® in type 2 diabetes under normal clinical practice conditions.
Interventions
DRUGbiphasic insulin aspart 30
No intervention is done. For study drug, start dose and frequency of administration to be prescribed by the physician as a result of normal clinical evaluation
Sponsors
Novo Nordisk A/S
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* All patients with type 2 diabetes, not adequately controlled on their current therapy, who were prescribed NovoMix® 30 FlexPen® as monotherapy, or in combination with OHA, in accordance with the approved labeling, are eligible for the survey.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patient and doctor's convenience | after 12 weeks of therapy |
| Change in prandial glucose increment (PGI) | after 12 weeks of therapy |
| Incidence of hypoglycaemia and other adverse drug reaction | after 12 weeks of therapy |
| Change in HbA1c | after 12 weeks of therapy |
| Change in post-prandial glucose (PPG) | after 12 weeks of therapy |
| Change in fasting plasma glucose (FPG) | after 12 weeks of therapy |
Secondary
| Measure | Time frame |
|---|---|
| Patient satisfaction on devices | after 12 weeks of treatment |
| Response of different patient profiles to NovoMix 30 therapy and patient profiles considered eligible for insulin treatment in physicians' routine clinical practice | For the duration of the study |
Countries
Indonesia
Outcome results
None listed